Autonomix Medical Files for Public Offering
Ticker: AMIX · Form: S-1 · Filed: Nov 1, 2024 · CIK: 1617867
Sentiment: neutral
Topics: ipo, registration-statement, medical-devices
TL;DR
Autonomix Medical is going public, get ready for some new medical tech stock!
AI Summary
Autonomix Medical, Inc. filed an S-1 registration statement on November 1, 2024, to register an unspecified number of securities. The company, incorporated in Delaware with its principal executive offices in The Woodlands, Texas, operates in the surgical and medical instruments sector. This filing indicates the company is preparing to offer its securities to the public, likely through an initial public offering (IPO) or a follow-on offering.
Why It Matters
This S-1 filing signals Autonomix Medical's intention to raise capital by selling its stock to the public, which could fund further development and expansion of its medical technologies.
Risk Assessment
Risk Level: medium — As an S-1 filing, it represents a company in the process of going public, which inherently carries risks associated with market reception and early-stage business execution.
Key Numbers
- 3841 — SIC Code (Indicates the company operates in the Surgical & Medical Instruments & Apparatus industry.)
- 471607810 — IRS Number (Employer Identification Number for Autonomix Medical, Inc.)
Key Players & Entities
- Autonomix Medical, Inc. (company) — Registrant
- November 1, 2024 (date) — Filing Date
- 333-282940 (registration_number) — SEC File Number
- 21 Waterway Avenue, Suite 300 The Woodlands, Texas 77380 (address) — Principal Executive Offices
- 713-588-6150 (phone_number) — Principal Executive Offices Phone
- Brad Hauser (person) — Chief Executive Officer
- Cavas S. Pavri (person) — Copies to Counsel
- Johnathan Duncan (person) — Copies to Counsel
- ArentFox Schiff LLP (company) — Counsel
FAQ
What is the total number of securities Autonomix Medical, Inc. intends to register?
The S-1 filing does not specify the total number of securities to be registered; it only states 'an unspecified number of shares of common stock'.
What is the primary business of Autonomix Medical, Inc.?
Autonomix Medical, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its SIC code 3841.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the SEC on November 1, 2024.
Who is the Chief Executive Officer of Autonomix Medical, Inc.?
Brad Hauser is the Chief Executive Officer of Autonomix Medical, Inc.
What is the principal executive office address for Autonomix Medical, Inc.?
The principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, Texas 77380.
Filing Stats: 4,761 words · 19 min read · ~16 pages · Grade level 14.3 · Accepted 2024-11-01 09:03:55
Key Financial Figures
- $0.001 — ne share of our common stock, par value $0.001 per share (the "Shares," "common stock"
- $14 — ing price for each Common Stock Unit is $14.31, based on the last reported sale pri
- $14.31 — price of our common stock on Nasdaq was $14.31 per share. There is no established publ
- $41.7 m — 2024, we had an accumulated deficit of $41.7 million, negative cash flows from operati
- $1.9 million — cash flows from operating activities of $1.9 million and working capital of $6.3 million, wh
- $6.3 m — of $1.9 million and working capital of $6.3 million, which raises substantial doubt a
- $5.2 million — and cash equivalents were approximately $5.2 million and cash used in operations for the sec
- $1.6 million — nd quarter ended September 30, 2024 was $1.6 million. Cash used in operations for the six mo
- $3.4 million — six months ended September 30, 2024 was $3.4 million. Our estimate of our cash and cash equ
- $450,000 — es for an initial annual base salary of $450,000 (subject to an annual review and increa
- $1,000,000 — et annual option grant will be equal to $1,000,000 divided by the Black-Scholes value per
- $150,000 — es for an initial annual base salary of $150,000 (subject to an annual review and increa
- $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc
Filing Documents
- amix20240726_s1.htm (S-1) — 2264KB
- ex_741224.htm (EX-1.1) — 288KB
- ex_741225.htm (EX-4.3) — 111KB
- ex_741226.htm (EX-4.4) — 114KB
- ex_741227.htm (EX-4.5) — 108KB
- ex_741228.htm (EX-4.6) — 122KB
- ex_741229.htm (EX-5.1) — 17KB
- ex_740746.htm (EX-23.1) — 2KB
- ex_741230.htm (EX-FILING FEES) — 73KB
- a01.jpg (GRAPHIC) — 44KB
- a02.jpg (GRAPHIC) — 60KB
- a03.jpg (GRAPHIC) — 44KB
- a04b.jpg (GRAPHIC) — 8KB
- a05.jpg (GRAPHIC) — 73KB
- a06.jpg (GRAPHIC) — 46KB
- a07.jpg (GRAPHIC) — 35KB
- afs.jpg (GRAPHIC) — 4KB
- amix.jpg (GRAPHIC) — 6KB
- b01.jpg (GRAPHIC) — 30KB
- logo2.jpg (GRAPHIC) — 19KB
- 0001437749-24-032896.txt ( ) — 3607KB
RISK FACTORS
RISK FACTORS 8 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 29
USE OF PROCEEDS
USE OF PROCEEDS 30 DIVIDEND POLICY 30
DILUTION
DILUTION 31 CAPITALIZATION 32
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33
BUSINESS
BUSINESS 41 MANAGEMENT 63 EXECUTIVE AND DIRECTOR COMPENSATION 66 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS AND DIRECTOR INDEPENDENCE 73
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 74
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 75
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 79 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 82
UNDERWRITING
UNDERWRITING 88 LEGAL MATTERS 93 EXPERTS 93 WHERE YOU CAN FIND MORE INFORMATION 94 INDEX TO FINANCIAL STATEMENTS 96 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the United States Securities and Exchange Commission ("SEC") to register the securities offered hereby under the Securities Act. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. You should carefully read this prospectus before deciding to invest in our securities. We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus out